OmniAb, Inc.
Julia Noodleman has work experience in multiple companies. In 2022, they worked as a Senior Research Associate at OmniAb, Inc. Julia joined the company in July 2022 and their role is ongoing. Prior to that, from August 2021 to May 2022, they worked as a Quality Control Laboratory Technician at Lucira Health. In 2021, they also worked as an Undergraduate Research Assistant at Mackeznie Lab from January to August.
Julia Noodleman attended the University of California, Davis from 2018 to 2021. Julia pursued a Bachelor of Science degree in Nutrition Biology during their time at the university.
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.